NLRP3-IN-95
NLRP3-IN-95 is an NLRP3 inflammasome inhibitor with an IC50 of 27 nM. NLRP3-IN-95 inhibits IL-1β secretion in PMA-differentiated THP-1 cells. NLRP3-IN-95 can be used in studies related to acute monocytic leukemia and inflammatory diseases.
For research use only. We do not sell to patients.
- CAS No.: 2771021-30-6
- Formula: C16H11F4IN4O2
- Molecular Weight:494.18
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
NLRP3 inflammasome 27 nM (IC50) |
In Vitro
NLRP3-IN-95 (compound 301) (1 h pretreatment, 2 h LPS (HY-D1056A1) + Nigericin (HY-127019) stimulation) inhibits IL-1β secretion in the supernatant of PMA-differentiated THP-1 cells with an IC50 of 27 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 2771021-30-6
-
Molecular Weight 494.18
-
Formula C16H11F4IN4O2
-
SMILES
O=C(CN1C(C2=CC=C(C=C2C(C(F)(F)F)C1)I)=O)NC3=NC=C(C=N3)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- NLRP3-IN-95
- 2771021-30-6
- NOD-like Receptor (NLR)
- NLRP3
- NLRP3 inflammasome
- IL-1β
- IL-18
- THP-1 cells
- PMA-differentiation
- LPS
- Nigericin
- IL-1β secretion
- ELISA
- supernatant
- IL-1β secretion assay
- inflammatory diseases
- ulcerative colitis
- skin cancer
- Parkinson's disease
- Crohn's disease
- Alzheimer's disease
- Inhibitor
- inhibitor
- inhibit